Carregant...

Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer

KRAS mutations are associated with tumor resistance to EGFR TKIs (erlotinib, gefitinib) and to monoclonal antibody against EGFR (cetuximab). Targeted treatment of mutated RAS patients is still considered as a challenge. Inhibitors of c-Met (onartuzumab or tiwantinib) and MEK (selumetinib—a dual inhi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Exp Med
Autors principals: Nicoś, Marcin, Krawczyk, Paweł, Jarosz, Bożena, Sawicki, Marek, Szumiłło, Justyna, Trojanowski, Tomasz, Milanowski, Janusz
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2015
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4844634/
https://ncbi.nlm.nih.gov/pubmed/25902737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10238-015-0349-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!